BioSpace News Archive

As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world.

Zomedica Corp. announced that Larry Heaton, Zomedica’s Chief Executive Officer, is scheduled to provide a company overview and its prospects for growth at the Dawson James Securities Small Cap Growth Conference on October 12, 2022 at the Wyndham Grand Hotel in Jupiter, Florida.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the commercial launch of Reline® Cervical, a new fixation system for posterior cervical fusion (PCF), in targeted regions.

Kadimastem Ltd. has been granted its third patent approval for the company’s innovative cell selection and enrichment technology and its use in the production of IsletRx, the company’s treatment and potential cure for diabetes.

Veeva Systems announced two new Veeva Crossix solutions to help life sciences companies execute and optimize omnichannel marketing campaigns.

RetinAI Medical AG (“RetinAI”), is a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA.

Nephros, Inc. announced it has shipped 3,000 commercial water filters as part of its ongoing annual contract with Donastar Enterprises LLC and Tractor Beverage Co. in service of a national chain of fast-casual restaurants.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program.

Aquestive Therapeutics, Inc. today announced it has entered a license, and supply agreement for Libervant™ (diazepam) Buccal Film with Pharmanovia, a global lifecycle management healthcare company, for treatment of prolonged or acute, convulsive seizures.

Nuvectis Pharma, Inc. today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in translational science and clinical research that will help guide the Company’s research and development strategy.